Tokyo -- Kaneka Corporation will appeal a September 2, 2026 ruling by the U.S. District Court for the Eastern District of New York that invalidated its U.S. Patent No. 7,829,080 covering reduced coenzyme Q10, known as ubiquinol.
New York court dismisses infringement case on enablement grounds
The court dismissed Kaneka's litigation against Cocrystal Technology (Jiaxing) Co., Ltd. and Cocrystal Health Industry (Zhejiang) Co., Ltd., ruling the '080 Patent invalid for lack of enablement. The case, filed October 5, 2023 under case number 1:23-cv-7483-SJB-SDE, had alleged that CoCrystal's ubiquinol supplements infringed claims 5 and 15 of the patent.
Kaneka cites conflicting prior ruling from Delaware court
Kaneka disputes the New York court's findings, noting it had submitted test data demonstrating significant utility during the patent's application process. The company points to a prior decision by a District Court in Delaware that upheld the same patent as valid, creating a direct conflict between the two rulings.
Kaneka moves to escalate dispute to Federal Circuit
Kaneka confirmed it will immediately appeal the New York decision to the Federal Circuit Court of Appeals. The company stated it will continue to enforce its intellectual property rights related to reduced coenzyme Q10 against parties it views as infringing, including further action tied to the '080 Patent.